Cargando…

Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients

The aim of this study was to evaluate the role of WT1 expression after allogeneic stem cell transplantation (alloHSCT) in patients with acute myeloid leukemia (AML). We studied WT1 expression in bone marrow cells from 50 patients in complete remission on day +60 after transplant. WT1 was assessed on...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiusolo, Patrizia, Metafuni, Elisabetta, Minnella, Gessica, Giammarco, Sabrina, Bellesi, Silvia, Rossi, Monica, Sorà, Federica, Limongiello, Maria Assunta, Frioni, Filippo, Piccirillo, Nicola, Bianchi, Maria, Valentini, Caterina Giovanna, Teofili, Luciana, Sica, Simona, Bacigalupo, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471009/
https://www.ncbi.nlm.nih.gov/pubmed/36119469
http://dx.doi.org/10.3389/fonc.2022.994366
_version_ 1784788969586688000
author Chiusolo, Patrizia
Metafuni, Elisabetta
Minnella, Gessica
Giammarco, Sabrina
Bellesi, Silvia
Rossi, Monica
Sorà, Federica
Limongiello, Maria Assunta
Frioni, Filippo
Piccirillo, Nicola
Bianchi, Maria
Valentini, Caterina Giovanna
Teofili, Luciana
Sica, Simona
Bacigalupo, Andrea
author_facet Chiusolo, Patrizia
Metafuni, Elisabetta
Minnella, Gessica
Giammarco, Sabrina
Bellesi, Silvia
Rossi, Monica
Sorà, Federica
Limongiello, Maria Assunta
Frioni, Filippo
Piccirillo, Nicola
Bianchi, Maria
Valentini, Caterina Giovanna
Teofili, Luciana
Sica, Simona
Bacigalupo, Andrea
author_sort Chiusolo, Patrizia
collection PubMed
description The aim of this study was to evaluate the role of WT1 expression after allogeneic stem cell transplantation (alloHSCT) in patients with acute myeloid leukemia (AML). We studied WT1 expression in bone marrow cells from 50 patients in complete remission on day +60 after transplant. WT1 was assessed on unfractionated bone marrow mononuclear cells (MNC) and on CD34+ selected cells (CD34+). A ROC curve analysis identified 800 WT1 copies on CD34+ selected cells, as the best cut-off predicting relapse (AUC 0.842, p=0.0006, 85.7% sensitivity and 81.6% specificity) and 100 copies in MNC (AUC 0.819, p=0.007, 83.3% sensitivity and 88.2% specificity). Using the 800 WT1 copy cut off in CD34+ cells, the 2 year cumulative incidence of relapse was 12% vs 38% (p=0.005), and 2 year survival 88% vs 55% (p=0.02). Using the 100 WT1 copy cut off in unfractionated MNC, the 2 year cumulative incidence of relapse 13% vs 44% (p=0.01) and the 2 year survival 88% vs 55% (p=0.08). In a multivariate Cox analysis WT1 expression in CD34 cells proved to highly predictive of relapse (p=0.004); also WT1 expression on unfractionated cells predicted relapse (p=0.03). In conclusion, day-60 WT1 expression after allogeneic HSCT is a significant predictor of relapse, particularly when tested on CD34+ selected bone marrow cells.
format Online
Article
Text
id pubmed-9471009
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94710092022-09-15 Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients Chiusolo, Patrizia Metafuni, Elisabetta Minnella, Gessica Giammarco, Sabrina Bellesi, Silvia Rossi, Monica Sorà, Federica Limongiello, Maria Assunta Frioni, Filippo Piccirillo, Nicola Bianchi, Maria Valentini, Caterina Giovanna Teofili, Luciana Sica, Simona Bacigalupo, Andrea Front Oncol Oncology The aim of this study was to evaluate the role of WT1 expression after allogeneic stem cell transplantation (alloHSCT) in patients with acute myeloid leukemia (AML). We studied WT1 expression in bone marrow cells from 50 patients in complete remission on day +60 after transplant. WT1 was assessed on unfractionated bone marrow mononuclear cells (MNC) and on CD34+ selected cells (CD34+). A ROC curve analysis identified 800 WT1 copies on CD34+ selected cells, as the best cut-off predicting relapse (AUC 0.842, p=0.0006, 85.7% sensitivity and 81.6% specificity) and 100 copies in MNC (AUC 0.819, p=0.007, 83.3% sensitivity and 88.2% specificity). Using the 800 WT1 copy cut off in CD34+ cells, the 2 year cumulative incidence of relapse was 12% vs 38% (p=0.005), and 2 year survival 88% vs 55% (p=0.02). Using the 100 WT1 copy cut off in unfractionated MNC, the 2 year cumulative incidence of relapse 13% vs 44% (p=0.01) and the 2 year survival 88% vs 55% (p=0.08). In a multivariate Cox analysis WT1 expression in CD34 cells proved to highly predictive of relapse (p=0.004); also WT1 expression on unfractionated cells predicted relapse (p=0.03). In conclusion, day-60 WT1 expression after allogeneic HSCT is a significant predictor of relapse, particularly when tested on CD34+ selected bone marrow cells. Frontiers Media S.A. 2022-08-31 /pmc/articles/PMC9471009/ /pubmed/36119469 http://dx.doi.org/10.3389/fonc.2022.994366 Text en Copyright © 2022 Chiusolo, Metafuni, Minnella, Giammarco, Bellesi, Rossi, Sorà, Limongiello, Frioni, Piccirillo, Bianchi, Valentini, Teofili, Sica and Bacigalupo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Chiusolo, Patrizia
Metafuni, Elisabetta
Minnella, Gessica
Giammarco, Sabrina
Bellesi, Silvia
Rossi, Monica
Sorà, Federica
Limongiello, Maria Assunta
Frioni, Filippo
Piccirillo, Nicola
Bianchi, Maria
Valentini, Caterina Giovanna
Teofili, Luciana
Sica, Simona
Bacigalupo, Andrea
Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients
title Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients
title_full Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients
title_fullStr Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients
title_full_unstemmed Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients
title_short Day +60 WT1 assessment on CD34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients
title_sort day +60 wt1 assessment on cd34 selected bone marrow better predicts relapse and mortality after allogeneic stem cell transplantation in acute myeloid leukemia patients
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471009/
https://www.ncbi.nlm.nih.gov/pubmed/36119469
http://dx.doi.org/10.3389/fonc.2022.994366
work_keys_str_mv AT chiusolopatrizia day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients
AT metafunielisabetta day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients
AT minnellagessica day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients
AT giammarcosabrina day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients
AT bellesisilvia day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients
AT rossimonica day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients
AT sorafederica day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients
AT limongiellomariaassunta day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients
AT frionifilippo day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients
AT piccirillonicola day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients
AT bianchimaria day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients
AT valentinicaterinagiovanna day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients
AT teofililuciana day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients
AT sicasimona day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients
AT bacigalupoandrea day60wt1assessmentoncd34selectedbonemarrowbetterpredictsrelapseandmortalityafterallogeneicstemcelltransplantationinacutemyeloidleukemiapatients